Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million.
- The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million.
- In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock.
- All of the shares to be sold in the offering are to be sold by Janux.
- The offering is expected to close on or about March 4, 2024, subject to customary closing conditions.